Bennett Lawrence Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bennett Lawrence Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$3.8M	Sell	36,290 -16,355	-31%	-$1.71M	1.23%	30
2015 Q3	$5.54M	Buy	52,645 +7,520	+17%	+$1M	1.77%	23
2015 Q2	$6.17M	Sell	45,125 -2,055	-4%	-$255K	1.62%	26
2015 Q1	$5.88M	Buy	47,180 +24,750	+110%	+$2.62M	1.57%	28
2014 Q4	$2.03M	Buy	+22,430	New	+$1.87M	0.55%	60
2013 Q3	–	Sell	-37,050	Closed	-$2.06M	–	76
2013 Q2	$2.06M	Buy	+37,050	New	+$2.31M	0.39%	67

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's BMRN Position: Q4 2015 in Review

Bennett Lawrence Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 31% in Q4 2015, selling an estimated $1.71M and leaving 36,290 shares worth $3.8M. The position accounts for 1.23% of the portfolio, ranked #30.

Bennett Lawrence Management first reported a position in BMRN in Q2 2013 and has held it in 6 quarters since. The position peaked at $6.17M in Q2 2015. 389 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Bennett Lawrence Management held 36,290 shares of BioMarin Pharmaceuticals worth $3.8M as of Q4 2015.
Bennett Lawrence Management sold 16,355 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $1.71M.
BioMarin Pharmaceuticals made up 1.23% of Bennett Lawrence Management's portfolio in Q4 2015, its #30 holding.
Bennett Lawrence Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
Bennett Lawrence Management's BioMarin Pharmaceuticals position peaked at $6.17M in Q2 2015.
389 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Bennett Lawrence Management's 13F filing for Q4 2015, filed 16 Feb 2016.